drugset / Trial / NCT04987489
A Study of Etavopivat in Patients With Thalassemia or Sickle Cell Disease
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This clinical trial is a Phase 2 study that will evaluate the safety and clinical activity of etavopivat in patients with thalassemia or sickle cell disease and test how well etavopivat works to lower the number of red blood cell transfusions required and increase hemoglobin.
Timeline
- Start
- 2022-03-28
- Primary completion
- 2025-09-03
- Completion
- 2025-09-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Etavopivat | Small molecule | 400 mg | Oral |